Worse health quality outcomes found with endocrine therapy after breast‐conserving surgery

says that the study is important because it shows that T-DXd could become the new standard of care for patients with HR+, HER2-low, or HER2-ultralow metastatic breast cancer."These data underscore the potential for treatment with T-DXd across the spectrum of HR+ breast cancer, further redefining the treatment of metastatic breast cancer," he says.Oladapo Yeku, MD, PhD, associate editor of NEJM Evidence, said in an audio interview that the "study supports the hypothesis that antibody-drug conjugates, such as trastuzumab deruxtecan, are effective in earlier lines of treatment even when patients have not been exposed to conventional cytotoxic chemotherapy." 3 When he was asked what factors should be considered when one is considering using T-DXd or chemotherapy in this setting, he cited the different types of toxicities associated with each type of treatment.The study found that more patients in the T-DXd group than the chemotherapy group experienced grade 3 or higher adverse events (52.8% vs. 44.4%).Notably, more patients treated with T-DXd experienced interstitial lung disease or pneumonitis (22.3% vs. 0.2% in the chemotherapy group) and left ventricular dysfunction (8.1% vs. 3.8%).Dr Yeku highlighted the potentially serious adverse event of interstitial lung disease in patients treated with T-DXd and said that the finding underscores the need for ongoing vigilance in patients receiving this treatment.